Thanks Lia. So, if it is the medical organizations -- not the FDA -- that put out the guidelines on preferred treatment sequence, then no further trials should be required. Given that, I am getting more comfortable with your assumption that adoption rates for Afrezza could be much faster than I was originally expecting. I also agree that the Afinity 2 trials will almost certainly show superiority. I would be very surprised it adding insulin didn't improve the participants' A1C levels.
It seems that the next step for Mannkind management is to educate the medical organizations so that they will recommend Afrezza as a first-line drug.
